FDA Disputes Study On Breast Implant Safety
Executive Summary
US FDA has taken the rare step of publicly disputing a study that seemed to show elevated risks of long-term adverse events associated with silicone breast implants.
You may also be interested in...
FDA AdComm Will Address Breast Implant Risks, Benefits At March Meeting
US FDA’s General and Plastic Surgery Devices advisory panel will meet for two days in March to explore the risks and benefits of both silicone gel-filled and saline-filled breast implants.
Study Highlights Autoimmune, CTD Issues In Women Who Had Breast Implants
Early results of a new study of 300 women who previously had breast implants, and a review of longer-term follow-up of patients who had their implants removed, found more patients have suffered autoimmune issues and connective tissue disease than have come out in FDA-mandated studies, according to the National Center for Health Research. NCHR was critical of FDA's and industry's approach to post-market surveillance of breast implants.
Cases Of Rare Lymphoma Linked To Breast Implants Increase
US FDA is now aware of 414 cases of breast implant-associated anaplastic large cell lymphoma. The agency says that updated medical literature estimates of the lifetime risk of textured breast implanted patients developing BIA-ALCL range between 1 in 3,817 to 1 in 30,000.